Fennec Pharmaceuticals (NASDAQ:FENC) shareholder returns have been respectable, earning 41% in 3 years

One simple way to benefit from the stock market is to buy an index fund. But if you choose individual stocks with prowess, you can make superior returns. For example, the Fennec Pharmaceuticals Inc. (NASDAQ:FENC) share price is up 41% in the last three years, clearly besting the market return of around 34% (not including dividends).

Since it's been a strong week for Fennec Pharmaceuticals shareholders, let's have a look at trend of the longer term fundamentals.

See our latest analysis for Fennec Pharmaceuticals

Fennec Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Fennec Pharmaceuticals' revenue trended up 123% each year over three years. That's much better than most loss-making companies. The share price rise of 12% per year throughout that time is nice to see, and given the revenue growth, that gain seems somewhat justified. So now might be the perfect time to put Fennec Pharmaceuticals on your radar. If the company is trending towards profitability then it could be very interesting.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

If you are thinking of buying or selling Fennec Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Investors in Fennec Pharmaceuticals had a tough year, with a total loss of 37%, against a market gain of about 27%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 1.3% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Fennec Pharmaceuticals better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Fennec Pharmaceuticals (of which 1 is concerning!) you should know about.

Of course Fennec Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.